Value proposition

Leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs

Aitia is the leader in the development and application of Causal AI and Digital Twins to discover the next generation of therapies for neurodegenerative diseases and Oncology. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden circuitry of human biology to identify novel targets driving disease and focused patient recruitment for clinical development. Aitia has translated those insights into its Gemini Digital Twins (computational representations of disease), which the company is using to discover new breakthrough therapies.

Data Analytics, Bioinformatics, Genomics Data, Big Data, Causal AI, Drug Discovery, Virtual Patient, In silico trials, Clinical Trial, Virtual Patient, Drug Discovery, Target Discovery, multi-omic patient data, oncology, neurodegenerative disorders, Gemini Digital Twins, Digital Twins, Gemini, and Generative AI